MagedKhalilMD

Oncology • Allentown, PA

Hematologist Oncologist at Lehigh Valley Hospital

Request Appointment

Overview of Dr. Khalil

Dr. Maged Khalil is an oncologist in Allentown, PA and is affiliated with multiple hospitals in the area, including Lehigh Valley Hospital-Cedar Crest and Lehigh Valley Health Network - Muhlenberg. He received his medical degree from Cairo University School of Medicine and has been in practice 18 years. He is one of 44 doctors at Lehigh Valley Hospital-Cedar Crest and one of 18 doctors at Lehigh Valley Health Network - Muhlenberg who specialize in Oncology. He has 8 publications and over 200 citings.

Office
1240 S Cedar Crest Blvd
Ste 103
Allentown, PA 18103
Book by Phone+1(610) 890-9656

Fax+1 610-402-7881

Education & Training

One Brooklyn Health System/Brookdale University Hospital and Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
One Brooklyn Health System/Brookdale University Hospital and Medical CenterResidency, Internal Medicine, 2000 - 2003
Cairo University School of MedicineClass of 1999

Certifications & Licensure

PA State Medical License 2007 - 2024
NY State Medical License 2003 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Home-Based Programs for Improving Sleep in Cancer Survivors Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) Start of enrollment: 2017 Mar 26
Active, not recruiting
Phase 2
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Start of enrollment: 2020 Feb 05
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

29 citations
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan
Journal of Clinical Oncology. 2022-04-20
6 citations
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Robert Huddart, Arlene O. Siefker-Radtke, Arjun Vasant Balar, Mehmet Asim Bilen, Thomas Powles
Future Oncology. 2021-01-01
81 citations
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) S...
Ajjai Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra
Journal of Clinical Oncology. 2021-04-12